Neximmune Inc Ticker Symbol and Stock Exchange Information Explained

Neximmune Inc's ticker symbol is a unique identifier assigned to the company for trading purposes.

Neximmune Inc is listed on the NASDAQ stock exchange under the ticker symbol NXMI.

The NASDAQ stock exchange is a global electronic marketplace for buying and selling securities.

Neximmune Inc's stock can be traded on the NASDAQ exchange using the NXMI ticker symbol.

You might like: Comerica Inc Stock Price

NexImmune, Inc. is a biopharmaceutical company focused on advancing immunotherapies using its proprietary Artificial Immune Modulation (AIM) technology platform.

The AIM technology was originally developed at Johns Hopkins University and harnesses the body's immune system to orchestrate a targeted T cell response against diseases.

NexImmune is currently working on therapies aimed at treating cancer and other serious immune-mediated conditions.

The company has two key product candidates in clinical trials: NEXI-001 for treating acute myeloid leukemia (AML), and NEXI-002 for multiple myeloma (MM).

These candidates leverage the curative potential of the body's own T cells, engineered to target and destroy specific cancer cells.

NexImmune has a strong presence in the field of immuno-oncology, with a significant focus on advancing its innovative therapeutic candidates.

Readers also liked: Black Rifle Coffee Stock Symbol

NexImmune Inc is a biopharmaceutical company focused on advancing immunotherapies using its proprietary Artificial Immune Modulation (AIM) technology platform. This technology was originally developed at Johns Hopkins University.

NexImmune's AIM technology harnesses the body's immune system to orchestrate a targeted T cell response against diseases. The company's innovation is centered around the development of artificial antigen-presenting cells (aAPCs).

These aAPCs present specific antigens to T cells, stimulating a highly targeted immune response. This approach can be rapidly customized to direct immune attacks toward various foreign substances or diseased cells within the patient's body.

NexImmune has two key product candidates in clinical trials: NEXI-001 for treating acute myeloid leukemia (AML), and NEXI-002 for multiple myeloma (MM). These candidates leverage the curative potential of the body's own T cells, engineered to target and destroy specific cancer cells.

NexImmune's AIM technology has shown significant progress in generating pre-clinical data supporting its multi-antigen-specific T cell-directing products. This includes validation from collaborators at leading institutions.

Here are NexImmune's key product candidates currently in clinical trials:

The company has also extended its research collaboration with Yale University and JDRF, aiming to explore the use of NexImmune's AIM nanoparticles combined with anti-CD3 mAb for potential type 1 diabetes treatments. This partnership includes an additional $300,000 grant provided by JDRF.

Our company was founded in 2005 by a group of entrepreneurs who saw an opportunity to bring innovative technology solutions to the market.

The founders' vision was to create a company that would not only provide cutting-edge products but also foster a culture of innovation and collaboration.

The company's early years were marked by rapid growth, with revenue increasing by 20% year-over-year for the first three years.

By 2008, the company had already established itself as a leader in its industry, with a strong presence in key markets around the world.

The company's commitment to innovation continued to drive its growth, with the introduction of new products and services that met the evolving needs of its customers.

Today, the company is a global leader in its industry, with a diverse portfolio of products and services that help businesses and individuals alike.

Neximmune Inc's stock information can be found on the NASDAQ exchange under the ticker symbol NXMI.

The company's stock is a publicly traded security, allowing investors to buy and sell shares on the open market.

Neximmune Inc's stock price can fluctuate based on market conditions and investor sentiment.

You might enjoy: Mbia Inc Stock

A ticker symbol is a unique code that represents a publicly traded company on a stock exchange. It's usually 1-4 letters long and is used to identify the company's stock on financial platforms.

The ticker symbol is often derived from the company's name, but not always. For example, Apple's ticker symbol is AAPL, which is a shortened version of the company's name.

You can find a company's ticker symbol on financial websites, stock market apps, or even on the company's website itself. It's a crucial piece of information for investors and traders to keep track of their investments.

The ticker symbol is used for both domestic and international stocks, but the format may vary slightly. For instance, some international stocks may use a combination of letters and numbers to represent the company's name.

Worth a look: Brighthouse Financial Ticker Symbol

Stock exchanges are platforms where buyers and sellers trade securities, such as stocks, bonds, and commodities. They provide a marketplace for investors to buy and sell securities.

The New York Stock Exchange (NYSE) is one of the largest stock exchanges in the world, with a market capitalization of over $20 trillion. It was founded in 1792.

Stock exchanges are regulated by government agencies to ensure fair and transparent trading practices. The Securities and Exchange Commission (SEC) is the primary regulator of stock exchanges in the United States.

Trading on stock exchanges can be done through a brokerage account, which allows investors to buy and sell securities electronically. This process is known as online trading.

The stock exchange is open for trading on weekdays, typically from 9:30 am to 4:00 pm Eastern Time.

Neximmune Inc Stock News is a valuable resource for investors and traders looking for the latest updates on the company's stock performance. NexImmune, Inc. (Nasdaq: NEXI) is an emerging biopharmaceutical company focused on advancing immunotherapies using its proprietary Artificial Immune Modulation (AIM) technology platform.

The AIM technology platform was originally developed at Johns Hopkins University and harnesses the body's immune system to orchestrate a targeted T cell response against diseases. This approach can be rapidly customized to direct immune attacks toward various foreign substances or diseased cells within the patient's body.

NexImmune has two key product candidates in clinical trials: NEXI-001 for treating acute myeloid leukemia (AML) and NEXI-002 for multiple myeloma (MM). These candidates leverage the curative potential of the body's own T cells, engineered to target and destroy specific cancer cells.

The company recently announced significant progress in generating pre-clinical data supporting their multi-antigen-specific T cell-directing products. This includes validation from collaborators at leading institutions, underlining the transformative potential of their AIM technology.

NexImmune extended its research collaboration with Yale University and JDRF to explore the use of NexImmune's AIM nanoparticles combined with anti-CD3 mAb for potential type 1 diabetes treatments. The extension includes an additional $300,000 grant provided by JDRF.

In October 2023, NexImmune executed a 1-for-25 reverse stock split, reducing its outstanding shares and addressing compliance with Nasdaq's minimum bid price requirement.

You might enjoy: Sentinel One Stock Symbol